Cardinal Health says it has acquired the assets and some liabilities ofSP Pharmaceuticals, a privately-held provider of drug development and manufacturing services for biotechnology and pharmaceutical products. Financial terms of the deal were not disclosed.
SP Pharmaceuticals, based in Albuquerque, New Mexico, has 250 employees and operates a 215,000-square-foot drug development and contract manufacturing center. It makes sterile, injectable drugs and biologics in liquid and freeze-dried formulations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze